Patents by Inventor Adam R. Renslo

Adam R. Renslo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210196695
    Abstract: Provided herein, inter alia, are methods and compounds for inhibiting K-Ras and for treating cancer.
    Type: Application
    Filed: October 28, 2020
    Publication date: July 1, 2021
    Inventors: Frank MCCORMICK, Adam R. Renslo, David Turner, Stephan Gysin, Anna E. Maciag, Oleg Chertov
  • Patent number: 11014955
    Abstract: Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine rings, namely, 1,2,4-trioxa-8-azaspiro[4.5] decane. Also disclosed is a pharmaceutical composition containing the compound and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: May 25, 2021
    Assignee: The Regents of the University of California
    Inventors: Adam R. Renslo, Erica M. W. Lauterwasser, Shaun D. Fontaine, Benjamin B. Spangler, James A. Wells
  • Patent number: 10857140
    Abstract: Provided herein, inter alia, are methods and compounds of formula (I) for inhibiting K-Ras and for treating cancer.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: December 8, 2020
    Assignees: The Regents of the University of California, Leidos Biomedical Research, Inc.
    Inventors: Frank McCormick, Adam R. Renslo, David Turner, Stephan Gysin, Anna E. Maciag, Oleg Chertov
  • Publication number: 20200317714
    Abstract: Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine rings, namely, 1,2,4-trioxa-8-azaspiro[4.5] decane. Also disclosed is a pharmaceutical composition containing the compound and a phannaceutically acceptable carrier.
    Type: Application
    Filed: April 8, 2020
    Publication date: October 8, 2020
    Inventors: Adam R. Renslo, Erica M.W. Lauterwasser, Shaun D. Fontaine, Benjamin B. Spangler, James A. Wells
  • Patent number: 10662215
    Abstract: Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine rings, namely, 1,2,4-trioxa-8-azaspiro[4.5]decane. Also disclosed is a pharmaceutical composition containing the compound and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: March 26, 2019
    Date of Patent: May 26, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Adam R. Renslo, Erica M. W. Lauterwasser, Shaun D. Fontaine, Benjamin B. Spangler, James A. Wells
  • Patent number: 10604493
    Abstract: Embodiments of the present disclosure, in one aspect, relate to a beta-lactamase inhibitor, pharmaceutical compositions including a beta-lactamase inhibitor, methods of treatment of a condition (e.g., infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: March 31, 2020
    Assignees: University of South Florida, The Regents of the University of California
    Inventors: Yu Chen, Derek Nichols, Adam R. Renslo, Priyadarshini Jaishankar, Erica M. W. Lauterwasser
  • Publication number: 20190375704
    Abstract: Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eIF2? phosphorylation, the Integrated Stress Response (ISR), and the unfolded protein response (UPR); for treating diseases; for increasing protein production, and for improving long-term memory.
    Type: Application
    Filed: May 21, 2019
    Publication date: December 12, 2019
    Inventors: Peter Walter, Carmela Sidrauski, Diego Acosta Alvear, Michelle R. Arkin, Christopher G. Wilson, Kean Hooi Ang, Brian R. Hearn, Punitha Vedantham, Adam R. Renslo, Mervyn Maze, Susana Vacas
  • Publication number: 20190284224
    Abstract: Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine rings, namely, 1,2,4-trioxa-8-azaspiro[4.5]decane. Also disclosed is a pharmaceutical composition containing the compound and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: March 26, 2019
    Publication date: September 19, 2019
    Inventors: Adam R. Renslo, Erica M.W. Lauterwasser, Shaun D. Fontaine, Benjamin B. Spangler, James A. Wells
  • Patent number: 10343981
    Abstract: Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eIF2? phosphorylation, the Integrated Stress Response (ISR), and the unfolded protein response (UPR); for treating diseases; for increasing protein production, and for improving long-term memory.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: July 9, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Peter Walter, Carmela Sidrauski, Diego Acosta Alvear, Michelle R. Arkin, Christopher G. Wilson, Kean Hooi Ang, Brian R. Hearn, Punitha Vedantham, Adam R. Renslo, Mervyn Maze, Susana Vacas
  • Patent number: 10287312
    Abstract: Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine rings, namely, 1,2,4-trioxa-8-azaspiro[4.5]decane. Also disclosed is a pharmaceutical composition containing the compound and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: May 14, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Adam R. Renslo, Erica M. W. Lauterwasser, Shaun D. Fontaine, Benjamin B. Spangler, James A. Wells
  • Publication number: 20180289683
    Abstract: Provided herein, inter alia, are methods and compounds for inhibiting K-Ras and for treating cancer.
    Type: Application
    Filed: May 6, 2016
    Publication date: October 11, 2018
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, LEIDOS BIOMEDICAL RESEARCH, INC.
    Inventors: Frank MCCORMICK, Adam R. RENSLO, David TURNER, Stephan GYSIN, Anna E. MACIAG, Oleg CHERTOV
  • Patent number: 9862684
    Abstract: Disclosed herein inter alia are compositions and methods useful in the treatment of diseases, for example pain, neurodegeneration, or mood disorders, and for modulating the activity of a K2P channel.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: January 9, 2018
    Assignee: The Regents of the University of California
    Inventors: Daniel L. Minor, Jr., Sviatoslav N. Bagriantsev, Adam R. Renslo
  • Publication number: 20170342020
    Abstract: Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eIF2? phosphorylation, the Integrated Stress Response (ISR), and the unfolded protein response (UPR); for treating diseases; for increasing protein production, and for improving long-term memory.
    Type: Application
    Filed: June 5, 2017
    Publication date: November 30, 2017
    Inventors: Peter Walter, Carmela Sidrauski, Diego Acosta Alvear, Michelle R. Arkin, Christopher G. Wilson, Kean Hooi Ang, Brian R. Hearn, Punitha Vedantham, Adam R. Renslo, Mervyn Maze, Susana Vacas
  • Patent number: 9708247
    Abstract: Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eIF2? phosphorylation, the Integrated Stress Response (ISR), and the unfolded protein response (UPR); for treating diseases; for increasing protein production, and for improving long-term memory.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: July 18, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Peter Walter, Carmela Sidrauski, Diego Acosta Alvear, Michelle R. Arkin, Christopher G. Wilson, Kean Hooi Ang, Brian R. Hearn, Punitha Vedantham, Adam R. Renslo, Mervyn Maze, Susana Vacas
  • Publication number: 20170088524
    Abstract: Embodiments of the present disclosure, in one aspect, relate to a beta-lactamase inhibitor, pharmaceutical compositions including a beta-lactamase inhibitor, methods of treatment of a condition (e.g., infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.
    Type: Application
    Filed: November 8, 2016
    Publication date: March 30, 2017
    Inventors: Yu Chen, Derek Nichols, Adam R. Renslo, Priyadarshini Jaishankar, Erica M. W. Lauterwasser
  • Patent number: 9556131
    Abstract: Embodiments of the present disclosure, in one aspect, relate to a beta-lactamase inhibitor, pharmaceutical compositions including a beta-lactamase inhibitor, methods of treatment of a condition (e.g., infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: January 31, 2017
    Assignees: UNIVERSITY OF SOUTH FLORIDA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Yu Chen, Derek Nichols, Adam R. Renslo, Priyadarshini Jaishankar, Erica M. W. Lauterwasser
  • Publication number: 20160362439
    Abstract: Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine rings, namely, 1,2,4-trioxa-8-azaspiro[4.5]decane. Also disclosed is a pharmaceutical composition containing the compound and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: February 13, 2015
    Publication date: December 15, 2016
    Inventors: Adam R. RENSLO, Erica M.W. LAUTERWASSER, Shaun D. FONTAINE, Benjamin B. SPANGLER, James A. WELLS
  • Publication number: 20160096800
    Abstract: Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eIF2? phosphorylation, the Integrated Stress Response (ISR), and the unfolded protein response (UPR); for treating diseases; for increasing protein production, and for improving long-term memory.
    Type: Application
    Filed: September 9, 2015
    Publication date: April 7, 2016
    Inventors: Peter Walter, Carmela Sidrauski, Diego Acosta Alvear, Michelle R. Arkin, Christopher G. Wilson, Kean Hooi Ang, Brian R. Hearn, Punitha Vedantham, Adam R. Renslo, Mervyn Maze, Susana Vacas
  • Publication number: 20160031814
    Abstract: Disclosed herein inter alia are compositions and methods useful in the treatment of diseases, for example pain, neurodegeneration, or mood disorders, and for modulating the activity of a K2P channel.
    Type: Application
    Filed: July 31, 2015
    Publication date: February 4, 2016
    Inventors: Daniel L. Minor, JR., Sviatoslav N. Bagriantsev, Adam R. Renslo
  • Publication number: 20140378516
    Abstract: Embodiments of the present disclosure, in one aspect, relate to a beta-lactamase inhibitor, pharmaceutical compositions including a beta-lactamase inhibitor, methods of treatment of a condition (e.g., infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.
    Type: Application
    Filed: January 4, 2013
    Publication date: December 25, 2014
    Inventors: Yu Chen, Derek Nichols, Adam R. Renslo, Priyadarshini Jaishankar, Erica M.W. Lauterwasser